CNS clinical trials suicidality and data collection : workshop summary
"The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience...
| Main Author: | |
|---|---|
| Corporate Authors: | , |
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Washington, D.C.
National Academies Press
2010, c2010
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | "The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description |
|---|---|
| Physical Description: | xii, 75 p. ill. 23 cm |
| ISBN: | 0309148839 9780309148832 |